ClinicalTrials.gg
CompletedNCT06378281Spark BATIRUpdated Nov 3, 2026

Testing a New Method to Improve Informed Consent in Prison Research

An interventional study of Modified teach-to-goal informed consent in ADHD, sponsored by Stéphanie Baggio. Completed at 2 sites in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Stéphanie Baggio · Not applicable, Interventional, and Basic science

How we know

Updated Nov 3, 2026Now CompletedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland — 5 open to participants now, 6 under way, 1 of them phase 3. Attention Deficit Disorder with Hyperactivity · Switzerland.

Enrollment
7th of 14
100 · median 80
Started
2024
with 1 other
No phase
7 of 18
3 open now
Registered
14th of 18
by date
Lead sponsor
2 of 18
Stéphanie Baggio

Among the 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland, this one is the 7th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2024, is one of 7 with no phase, and was the 14th registered.

Attention Deficit Disorder with Hyperactivity

1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

5 of the 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland, or all of them as a file.
02

Study summary

Understanding of informed consent is often limited in prison, due to unique challenges faced by detained people. This study will test a modified "teach-to-goal" informed consent process compared to standard procedures. Conducted within a larger study on psychiatric outcomes, it aims to enhance ethical practices for vulnerable populations.

Read the detailed description

Background and rationale. Informed consent is an ethical pillar of health-related research involving human subjects, but participants' understanding of informed consent is often limited. Informed consent is also a critical issue in prison research.

First, detained persons are deprived from liberty, a context that may undermine voluntary participation and autonomy. Second, detained persons have disproportionally low levels of education, literacy, and high rates of cognitive or substance- and psychiatric-related impairments. In Switzerland, a study conducted in the general population concluded that informed consent forms are too long and complex. Another study conducted in prison showed a full understanding of 5% in detained persons. Of note, a revision of the Federal Human Research Act (HRA) has just begun and includes propositions to strengthen informed consent. Nonetheless, few studies focused on understanding of informed consent in prison research and to our knowledge, no study with a robust methodology tested whether the most effective interventions in the general population are also effective in prison. Objective of the study. The overarching aim of this study is to estimate and improve understanding of informed consent in prison research, and better understanding characteristics associated with a low understanding. The informed consent process is a time-consuming process and studies may lack resources to ensure that participants provide fully informed consent. To fill in this critical research gap, this study will be embedded in a larger randomized controlled trial (RCT) ("parent-RCT") designed to improve psychiatric outcomes. We will use an RCT to compare two informed consent processes. Methods. This is a cross-sectional RCT (ratio 1:1) testing the effect of informed consent processes on understanding (primary endpoint) and evaluation (secondary endpoints) of informed consent. The research team and will not be blinded to the participants' group, but the statistician will be. Participants will be partially blinded. Data will be collected in four prisons among sentenced persons (n=100). The intervention will be modified "teach-to-goal" vs. standard informed consent process. In the modified teach-to-goal intervention, the participant is asked to describe the research procedures. Misconceptions are corrected by a study team member and the participant is asked to describe again the corresponding components. The procedure is iterated until correct and full understanding is reached. Analyses will include intention-to-treat bivariable and multivariable regressions. We will also explore associations between understanding and socio-demographic variables using logistic, linear or negative-binomial regressions, to identify characteristics associated with lower understanding. Expected results and impact. There is a growing recognition that prison research is needed. Improving informed consent in prison research therefore constitutes a critical but neglected issue, both as a separate research topic and for future research projects focusing on detained persons and more broadly, on vulnerable populations. Embedding a RCT on informed consent in an already existing RCT is an unconventional research process. We believe that it will provide "real (study) life" information on how informed consent is informed and ways to improve it. It will also ensure that ethical requirements are fully met in the parent-RCT. This study will thus provide scientific evidence on how to improve informed consent in prison research.

Results will be valuable for other vulnerable populations, including people with low levels of education and literacy and high burden of disease. We plan to publish results in a high-impact biomedical journal and to share them in international conferences and with Swiss cantonal Ethics Committees to raise awareness on informed consent as a core component of medical ethics in research, and more specifically, research involving vulnerable populations. The project may provide meaningful information for the revision of the HRA and help improving informed consent processes in Swiss research.

03

Conditions studied

  • ADHD

Keywords

  • Informed consent
  • Prison
  • Ethics
04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • screened in the parent-RCT
  • age ≥ 18 years
  • good command of French
  • absence of acute psychiatric disorder
  • providing written for study participation in the parent-RCT

Exclusion criteria

Exclusion Criteria:

- none.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • No intervention
    Standard informed consent

    According to ethical requirements of Swiss Human Research Act, the interviewer will explain the nature of the study, its purposes, duration, the potential risks and benefits it entails, and study procedures. He will inform that study participation is voluntary and that participants may withdraw at any time. He will also explain that the study is independent from the prison authorities. Participants will then be given time to read the informed consent, or, if they are not able to read, it will be read to them by the interviewer. The interviewer will answer all questions.

  • Experimental
    Modified teach-to-goal informed consent

    The standard process will first be used. After that, the interviewer will ask participants to summarize the content of the informed consent. The interviewer will correct not-well understood components and ask questions about forgotten components. In case of misconceptions, the participant will be asked to summarize again the corresponding components. A list of key components to be addressed will be developed by study team members, including experts in prison research and ethics, based on components listed in Art. 16 of the Swiss Human Research Act. The material of the informed consent of the parent-randomized controlled trial will be used.

    Other: Modified teach-to-goal informed consent

Interventions

  • OtherModified teach-to-goal informed consent

    Enhanced procedure to improve informed consent in vulnerable populations.

06

What researchers measure

Primary outcomes

  1. Understanding of the informed consent (binary)

    20 questions (true/false) evaluating whether the participant understood the information. A binary variable coded 1 if all questions are answered correctly and 0 otherwise will be computed.

    Time frame: Immediately after the intervention

Secondary outcomes

  1. Understanding of the informed consent (continuous)

    20 questions (true/false) evaluating whether the participant understood the information. A score between 0 and 20 will be developed.

    Time frame: Immediately after the intervention

  2. Evaluation of the informed consent

    10 questions evaluated on a Likert 6-point scale evaluating what the participants thought of the information. A score between 0 and 50 will be computed.

    Time frame: Immediately after the intervention

07

Study locations

2 sites
  • Geneva University Hospitals
    Geneva, Canton of Geneva 1211, Switzerland
  • Geneva University Hospitals
    Geneva, Canton of Geneva 1226, Switzerland
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Oct 2026, 29 months.

Of 480 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's 29 months is above that.

Counting every sponsor, half of 511 studies reached it within 23 months; a quarter within 11 and three quarters within 41.

Primary completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, last on Nov 3, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, last on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2024
First posted
Apr 22, 2024
StartActual
May 1, 2024
Primary completionActual
Oct 28, 2026was Sep 2026
CompletionActual
Oct 28, 2026was Sep 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 3, 2026
Primary completion
Sep 30, 2026→Oct 28, 2026 (actual)
moved 2 times, Oct 7, 2026 – Nov 3, 2026
Study completion
Sep 30, 2026→Oct 28, 2026 (actual)
moved 2 times, Oct 7, 2026 – Nov 3, 2026
Eligibility
Sex MALE→ALL; 1 inclusion criterion edited; 2 criteria removed
What changed in the criteria
  • RemovedInclusion Criteria:
  • RemovedExclusion Criteria:
Inclusion criteria
  • Editedinclusionscreened in the parent-RCT
Oct 7, 2026
Documents
Show all 2 updates
  1. Nov 3, 2026
    Recruiting→Completed
    Primary completion Oct 31, 2026→Oct 28, 2026 (now actual)
    Study completion Oct 31, 2026→Oct 28, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details
  2. Oct 7, 2026
    Primary completion Sep 30, 2026→Oct 31, 2026
    Study completion Sep 30, 2026→Oct 31, 2026
    Eligibility Sex MALE→ALL; 1 inclusion criterion edited; 2 criteria removed
    What changed in the criteria
    • RemovedInclusion Criteria:
    • RemovedExclusion Criteria:
    Inclusion criteria
    • Editedinclusionscreened in the parent-RCT
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06378281
Lead sponsor
Stéphanie Baggio
Collaborators
University of Bern, Leiden University, School of Health Sciences Fribourg, University Hospital, Geneva, University of Lausanne
Responsible party
Stéphanie Baggio (Prof. Dr. phil., University Hospital, Geneva) — Sponsor-investigator
First posted
Apr 22, 2024
Start date
May 1, 2024
Primary completion
Oct 28, 2026
Completion
Oct 28, 2026
Last update
Nov 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion